Staphylococcal and Streptococcal Superantigens

BIODEFENSE: Research Methodology and Animal Models

Volumn , Issue , 2005, Pages 291-319

  Krakauer, Teresa ^a   Stiles, Bradley G ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34250797635     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420038118-20     Document Type: Chapter

References (249)

1. Kotzin, B.L. et al, Superantigens and their potential role in human disease, Adv. Immunol., 54, 99, 1993.
2. Monday, S.R. and Bohach, G.A., Properties of Staphylococcus aureus enterotoxins and toxic shock syndrome toxin-1, in The Comprehensive Sourcebook of Bacterial Protein Toxins, Academic Press, London, 1999, chap. 33.
3. Schuberth, H-J. et al, Characterization of leukocytotoxic and superantigen-like factors produced by Staphylococcus aureus isolates from milk of cows with mastitis, Vet. Microbiol., 82, 187, 2000.
4. Fleischer, B. et al, An evolutionary conserved mechanism of T cell activation by microbial toxins. Evidence for different affinities of T cell receptor-toxin interaction, J. Immunol., 146, 11, 1991.
5. Smith, B.G. and Johnson, H, The effect of staphylococcal enterotoxins on the primary in vitro immune response, J. Immunol., 115, 575, 1975.
6. Poindexter, N.J. and Schlievert, P.M. Toxic-shock-syndrome toxin 1-induced proliferation of lymphocytes: comparison of the mitogenic response of human, murine, and rabbit lymphocytes, J. Infect. Dis., 153, 772, 1986.
7. Bhakdi, S., Muhly, M., and Fussle, R, Correlation between toxin binding and hemolytic activity in membrane damage by staphylococcal alpha-toxin, Infect. Immun., 46, 318, 1984.
8. Bhakdi, S. and Muhly, M, Decomplementation antigen, a possible determinant of staphylococcal pathogenicity, Infect. Immun., 47, 41, 1985.
9. Kreiswirth, B. et al, Evidence for a clonal origin of methicillin resistance in Staphylococcus aureus, Science, 259, 227, 1993.
10. CDC, Reduced susceptibility of Staphylococcus aureus to vancomycin-Japan, 1996. 1997, Morb. Mortal. Weekly Rep., 46, 624.
11. CDC. Staphylococcus aureus resistance to vancomycin-United States, 2002. 2002, Morb. Mortal. Weekly Rep., 51, 565.
12. Kim, T. et al, The economic impact of methicillin-resistant Staphylococcus aureus in Canadian hospitals. Infect. Cont. Hosp. Epidemiol., 22, 99, 2001.
13. Vriens, M. et al, Costs associated with a strict policy to eradicate methicillin-resistant Staphylococcus aureus in a Dutch university medic center: a 10-year survey, Eur. J. Clin. Microbiol. Infect. Dis., 21, 782, 2002.
14. Carmeli, Y. et al, Health and economic outcomes of vancomycin-resistant enterococci, Arch. Intern. Med., 162, 2223, 2002.
15. Capitano, B. et al, Cost effect of managing methicillin-resistant Staphylococcus aureus in a long-term care facility, J. Am. Geriatr. Soc., 51, 10, 2003.
16. Dinges, M.M., Orwin, P.M., and Schlievert, P.M, Exotoxins of Staphylococcus aureus, Clin. Microbiol. Rev., 13, 16, 2000.
17. Omoe, K. et al, Identification and characterization of a new staphylococcal enterotoxin-related putative toxin encoded by two kinds of plasmids, Infect. Immun., 71, 6088, 2003.
18. Bergdoll, M.S, Monkey feeding test for staphylococcal enterotoxin, Meth. Enzymol., 165, 324, 1988.
19. Loir, L., Baron, F., and Gautier, M, Staphylococcus aureus and food poisoning, Genet. Mol. Res., 2, 63, 2003.
20. McGann, V.G., Rollins, J.B., and Mason, D.W, Evaluation of resistance to staphylococcal enterotoxin B: naturally acquired antibodies of man and monkey, J. Infect. Dis., 124, 206, 1971.
21. Holmberg, S.D. and Blake, P.A, Staphylococcal food poisoning in the United States. New facts and old misconceptions, JAMA, 251, 487, 1984.
22. Jett, M. et al, Staphylococcus aureus enterotoxin B challenge of monkeys: correlation of plasma levels of arachidonic acid cascade products with occurrence of illness, Infect. Immun., 58, 3494, 1990.
23. Scheuber, P.H. et al, Cysteinyl leukotrienes as mediators of staphylococcal enterotoxin B in the monkey, Eur. J. Clin. Invest., 17, 455, 1987.
24. Ulrich, R.G. et al., Staphylococcal enterotoxin B and related pyrogenic toxins, in Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare, Zajtchuk, R., Ed., US Dept. Army, Washington DC, 1997, chap. 31.
25. Todd, J., Fishaut, M., Kapral, F., and Welch, T. Toxic-shock syndrome associated with phage-group-I staphylococci, Lancet, 2, 1116, 1978.
26. Shands, K.N. et al. Toxic-shock syndrome in menstruating women: association with tampon use and Staphylococcus aureus and clinical features in 52 cases, N. Eng. J. Med., 303, 1436, 1980.
27. Schlievert, P.M. et al, Identification and characterization of an exotoxin from Staphylococcus aureus associated with toxic-shock syndrome, J. Infect. Dis., 143, 509, 1981.
28. Crass, B.A. and Bergdoll, M.S, Involvement of staphylococcal enterotoxins in nonmenstrual toxic shock syndrome, J. Clin. Microbiol., 23, 1138, 1986.
29. McCormick, J.K., Yarwood, J.M., and Schlievert, P.M, Toxic shock syndrome and bacterial superantigens: an update, Ann. Rev. Microbiol., 55, 77, 2001.
30. Mills, J. et al, Control of production of toxic-shock-syndrome toxin-1 (TSST-1) by magnesium ion, J. Infect. Dis., 151, 1158, 1985.
31. Schlievert, P.M., Blomster, D.A., and Kelly, J.A, Toxic shock syndrome Staphylococcus aureus: effect of tampons on toxic shock syndrome toxin 1 production, Obstet. Gynecol., 64, 666, 1984.
32. Bergdoll, M.S. et al. A new staphylococcal enterotoxin, enterotoxin F, associated with toxic-shock-syndrome Staphylococcus aureus isolates, Lancet, 1, 1017, 1981.
33. Reiser, R.F. et al, Purification and some physicochemical properties of toxic-shock toxin, Biochemistry, 22, 3907, 1983.
34. Schlievert, P.M, Alteration of immune function by staphylococcal pyrogenic exotoxin type C: possible role in toxic-shock syndrome, J. Infect. Dis., 147, 391, 1983.
35. Ikejima, T. et al, Induction by toxic-shock-syndrome toxin-1 of a circulating tumor necrosis factor-like substance in rabbits and of immunoreactive tumor necrosis factor and interleukin-1 from human mononuclear cells, J. Infect. Dis., 158, 1017, 1988.
36. Parsonnet, J, Mediators in the pathogenesis of toxic shock syndrome: overview, Rev. Infect. Dis., 11, S263, 1989.
37. Freedman, J.D. and Beer, D.J, Expanding perspectives on the toxic shock syndrome, Adv. Intern. Med., 36, 363, 1991.
38. Bohach, G.A. et al, Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses, Crit. Rev. Microbiol., 17, 251, 1990.
39. Garbe, P.L. et al, Staphylococcus aureus isolates from patients with nonmenstrual toxic shock syndrome. Evidence for additional toxins, JAMA, 252, 2538, 1985.
40. Andrews, M-M. et al, Recurrent nonmenstrual toxic shock syndrome: clinical manifestations, diagnosis, and treatment, Clin. Infect. Dis., 32, 1470, 2001.
41. Bonventre, P.F. et al, Antibody responses to toxic-shock-syndrome (TSS) toxin by patients with TSS and by healthy staphylococcal carriers, J. Infect. Dis., 150, 662, 1984.
42. Vergeront, J.M. et al, Prevalence of serum antibody to staphylococcal enterotoxin F among Wisconsin residents: implications for toxic-shock syndrome, J. Infect. Dis., 148, 692, 1983.
43. Notermans, S. et al, Serum antibodies to enterotoxins produced by Staphylococcus aureus with special reference to enterotoxin F and toxic shock syndrome, J. Clin. Microbiol., 18, 1055, 1983.
44. Mahlknecht, U. et al, The toxic shock syndrome toxin-1 induces anergy in human T cells in vivo, Human Immunol., 45, 42, 1996.
45. Hofer, M.F. et al, Differential effects of staphylococcal toxic shock syndrome toxin-1 on B cell apoptosis, Proc. Natl. Acad. Sci. USA, 93, 5425, 1996.
46. Stiles, B.G., Krakauer, T., and Bonventre, P.F, Biological activity of toxic shock syndrome toxin 1 and a site-directed mutant, H135A, in a lipopolysaccharide-potentiated mouse lethality model, Infect. Immun., 63, 1229, 1995.
47. Stiles, B.G. et al, Mucosal vaccination with recombinantly attenuated staphylococcal enterotoxin B and protection in a murine model, Infect. Immun., 69, 2031, 2001.
48. Nilsson, I.M. et al, Protection against Staphylococcus aureus sepsis by vaccination with recombinant staphylococcal enterotoxin A devoid of superantigenicity, J. Infect. Dis., 180, 1370, 1999.
49. Bavari, S., Dyas, B., and Ulrich, R.G, Superantigen vaccines: a comparative study of genetically attenuated receptor-binding mutants of staphylococcal enterotoxin A, J. Infect. Dis., 174, 338, 1996.
50. McCormick, J.K. et al, Development of streptococcal pyrogenic exotoxin C vaccine toxoids that are protective in the rabbit model of toxic shock syndrome, J. Immunol., 165, 2306, 2000.
51. Roggiani, M. et al, Toxoids of streptococcal pyrogenic exotoxin A are protective in rabbit models of streptococcal toxic shock syndrome, Infect. Immun., 68, 5011, 2000.
52. Gampfer, J. et al, Double mutant and formaldehyde inactivated TSST-1 as vaccine candidates for TSST-1-induced toxic shock syndrome, Vaccine, 20, 1354, 2002.
53. Ulrich, R.G., Olson, M.A., and Bavari, S, Development of engineered vaccines effective against structurally related bacterial superantigens, Vaccine, 16, 1857, 1998.
54. Hu, D.L. et al, Vaccination with nontoxic mutant toxic shock syndrome toxin-1 protects against Staphylococcus aureus infection, J. Infect. Dis., 188, 743, 2003.
55. Prescott, L.M., Harley, J.P., and Klein, D.A. Microbiology, 5th ed., McGraw-Hill, Boston, 2002, 784.
56. Stevens, D.L, Invasive group A streptococcus infections, Clin. Infect. Dis., 14, 2, 1992.
57. Stevens, D.L, The toxins of group A streptococcus, the flesh eating bacteria, Immunol. Invest., 26, 129, 1997.
58. Marrack, P. and Kappler, J, The staphylococcal enterotoxins and their relatives, Science, 248, 705, 1990.
59. Choi, Y. et al, Interaction of Staphylococcus aureus toxin “superantigens” with human T cells, Proc. Natl. Acad. Sci. USA, 86, 8941, 1989.
60. Webb, S.R. and Gascoigne, N.R. T-cell activation by superantigens, Curr. Opinion Immunol., 6, 467, 1994.
61. Blackman, M.A. and Woodland, D.L, In vivo effects of superantigens, Life Sci., 57, 1717, 1995.
62. Johnson, H.M., Torres, B.A., and Soos, J.M. Superantigens: structure and relevance to human disease, Proc. Soc. Exp. Biol. Med., 212, 99, 1996.
63. Florquin, S. and Aaldering, L. Superantigens: a tool to gain new insight into cellular immunity, Res. Immunol., 148, 373, 1997.
64. Li, H. et al, The structural basis of T cell activation by superantigens, Ann. Rev. Immunol., 17, 435, 1999.
65. Ribeiro-Dias, F. et al, Mycoplasma arthritidis superantigen (MAM)-induced macrophage nitric oxide release is MHC class II restricted, interferon gamma dependent, and toll-like receptor 4 independent, Exp. Cell Res., 286, 345, 2003.
66. Ohmen, J. D. et al, Evidence for a superantigen in human tuberculosis, Immunity, 1, 35, 1994.
67. Legaard, P.K., LeGrand, R.D., and Misfeldt, M.L, The superantigen Pseudomonas exotoxin A requires additional functions from accessory cells for T lymphocyte proliferation, Cell Immunol., 135, 372, 1991.
68. Proft, T. and Fraser, J.D, Bacterial superantigens, Clin. Exp. Immunol., 133, 299, 2003.
69. Proft, T. et al, Superantigens and streptococcal toxic shock syndrome, Emerg. Infect. Dis., 9, 1211, 2003.
70. Proft, T. et al, Identification and characterization of novel superantigens from Streptococcus pyogenes, J. Exp. Med., 189, 89, 1999.
71. Stuart P.M. et al, Characterization of human T-cell responses to Yersinia enterocolitica superantigen, Hum. Immunol., 43, 269, 1995.
72. Abe J. et al, Pathogenic role of a superantigen in Yersinia pseudotuberculosis infection, Adv. Exp. Med. Biol., 529, 459, 2003.
73. Dobrescu, D. et al. Enhanced HIV-1 replication in V beta 12 T cells due to human cytomegalovirus in monocytes: evidence for a putative herpesvirus superantigen, Cell, 82, 753, 1995.
74. Sutkowski, N. et al. An Epstein-Barr virus-associated superantigen, J. Exp. Med., 184, 971, 1996.
75. Yao, Z. et al, Herpesvirus saimiri open reading frame 14, a protein encoded by T lymphotropic herpesvirus, binds to MHC class II molecules and stimulates T cell proliferation, J. Immunol., 156, 3260, 1996.
76. Torres, B.A. et al, Characterization of Nef-induced CD4 T cell proliferation, Biochem. Biophys. Res. Commun., 225, 54, 1996.
77. Acha-Orbea, H. and MacDonald, H.R, Superantigens of mouse mammary tumor virus, Ann. Rev. Immun., 13, 459, 1995.
78. Lafon, M, Rabies virus superantigen, Res. Immunol., 144, 209, 1993
79. Betley, M.J. et al, Staphylococcal enterotoxin A gene is associated with a variable genetic element, Proc. Natl. Acad. Sci. USA, 81, 5179, 1984.
80. Betley, M.J., Borst, D.W., and Regassa, L.B, Staphylococcal enterotoxins, toxic shock syndrome toxin and streptococcal pyrogenic exotoxins: a comparative study of their molecular biology, Chem. Immunol., 55, 1, 1992.
81. Singh, B.R., Fen-Ni, F., and Ledoux, D.N, Crystal and solution structures of superantigenic staphylococcal enterotoxins compared, Struct. Biol., 1, 358, 1994.
82. Swaminathan, S. et al, Crystal structure of staphylococcal enterotoxin B, a superantigen, Nature, 359, 801, 1992.
83. Chen J. et al. MMDB: Entrez’s 3D-structure database. Nucl. Acid Res., 31, 474, 2003.
84. Papageorgiou A.C., H.S. Tranter, and K.R. Acharya, Crystal structure of microbial superantigen staphylococcal enterotoxin B at 1.5 angstrom resolution: implications for superantigen recognition by MHC class II molecules and T cell receptors, J. Mol. Biol., 277, 61, 1998.
85. Papageorgiou A.C. et al, The refined crystal structure of toxic shock syndrome toxin-1 at 2.07 angstrom resolution, J. Mol. Biol., 260, 553, 1996.
86. Papageorgiou, A.C. et al, Structural basis for the recognition of superantigen streptococcal pyrogenic exotoxin A (SpeA1) by MHC class II molecules and T-cell receptors, EMBO J., 18, 9, 1999.
87. Arcus, V.L. et al, Conservation and variation in superantigen structure and activity highlighted by the three-dimensional structures of two new superantigens from Streptococcus pyogenes, J. Mol. Biol., 299, 157, 2000.
88. Hurley, J.M. et al, Identification of class II major histocompatibility complex and T cell receptor binding sites in the superantigen toxic shock syndrome toxin 1, J. Exp. Med., 181, 2229, 1995.
89. Kappler, J.W. et al, Mutations defining functional regions of the superantigen staphylococcal enterotoxin B, J. Exp. Med., 175, 387, 1992.
90. Kum, W.W. and Chow, A.W, Inhibition of staphylococcal enterotoxin A-induced superantigenic and lethal activities by a monoclonal antibody to toxic shock syndrome toxin-1, J. Infect. Dis., 183, 1739, 2001.
91. Bavari, S., Ulrich, R.G., and LeClaire, R.D. Cross-reactive antibodies prevent the lethal effects of Staphylococcus aureus superantigens, J. Infect. Dis., 180, 1365, 1999.
92. Thompson, N.E., Ketterhagen, M.J., and Bergdoll, M.S, Monoclonal antibodies to staphylococcal enterotoxin B and C: cross-reactivity and localization of epitopes on tryptic fragments, Infect. Immun., 45, 281, 1984.
93. Spero, L., Morlock, B.A., and Metzger, J.F, On the cross-reactivity of staphylococcal enterotoxins A, B, and C, J. Immunol., 120, 86, 1978.
94. Bohach, G.A. et al. Cross-neutralization of staphylococcal and streptococcal pyrogenic toxins by monoclonal and polyclonal antibodies, Infect. Immun., 56, 400, 1988.
95. Kline, J.B. and Collins, C.M, Analysis of the superantigenic activity of mutant and allelic forms of streptococcal pyrogenic exotoxin A, Infect. Immun., 64, 861, 1996.
96. Mollick, J.A. et al, Staphylococcal exotoxin activation of T cells. Role of exotoxin-MHC class II binding affinity and class II isotype, J. Immunol., 146, 463, 1991.
97. Proft T. et al, Immunological and biochemical characterization of streptococcal pyrogenic exotoxins I and J (SPE-I and SPE-J) from Streptococcus pyogenes, J. Immunol., 166, 6711, 2001.
98. Yagi, J., Rath, J.S., and Janeway, C.A, Control of T cell responses to staphylococcal enterotoxins by stimulator cell MHC class II polymorphism, J. Immunol., 147, 1398, 1991.
99. Herrmann, T., Acolla, R.S., and MacDonald, H.R, Different staphylococcal enterotoxins bind preferentially to distinct major histocompatibility complex class II isotypes, Eur. J. Immunol., 19, 2171, 1989.
100. Herman, A. et al. HLA-DR alleles differ in their ability to present staphylococcal enterotoxins to T cells, J. Exp. Med., 172, 709, 1990.
101. Chintagumpala, M.M., Mollick, J.A., and Rich, R.R, Staphylococcal toxins bind to different sites on HLA-DR, J. Immunol., 147, 3876, 1991.
102. Imanishi, K., Igarashi, H., and Uchiyama, T, Relative abilities of distinct isotypes of human major histocompatibility complex class II molecules to bind streptococcal pyrogenic exotoxin types A and B, Infect. Immun., 60, 5025, 1992.
103. See, R.H., Krystal, G., and Chow, A.W, Receptors for toxic shock syndrome toxin-1 and staphylococcal enterotoxin A on human blood monocytes, Can. J. Microbiol., 38, 937, 1992.
104. Hudson, K.R. et al, Staphylococcal enterotoxin A has two cooperative binding sites on major histocompatibility complex class II, J. Exp. Med., 182, 711, 1995.
105. Tiedemann, R.E., and Fraser, J.D. Cross-linking of MHC class II molecules by staphylococcal enterotoxin A is essential for antigen-presenting cell and T cell activation, J. Immunol., 157, 3958, 1996.
106. Thibodeau, J. et al, Molecular characterization and role in T cell activation of staphylococcal enterotoxin A binding to the HLA-DR alpha-chain, J. Immunol., 158, 3698, 1997.
107. Ulrich, R.G., Bavari, S., and Olson, M.A, Staphylococcal enterotoxins A and B share a common structural motif for binding class II major histocompatibility complex molecules, Nat. Struct. Biol., 2, 554, 1995.
108. Mehindate, K. et al. Cross-linking of major histocompatibility complex class II molecules by staphylococcal enterotoxin A superantigen is a requirement for inflammatory cytokine gene expression, J. Exp. Med., 182, 1573, 1995.
109. Jardetzky, T.S. et al. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen, Nature, 368, 711, 1994.
110. Kim, J. et al, Toxic shock syndrome toxin-1 complexed with a class II major histocompatibility molecule HLA-DR1, Science, 266, 1870, 1994.
111. Kum, W.W., Wood, J.A., and Chow, A.W. A mutation at glycine residue 31 of toxic shock syndrome toxin-1 defines a functional site critical for major histocompatiblity complex class II binding and superantigenic activity, J. Infect. Dis., 174, 1261, 1996.
112. Li, P.L. et al, The superantigen streptococcal pyrogenic exotoxin C (SPE-C) exhibits a novel mode of action, J. Exp. Med., 186, 375, 1997.
113. Kappler, J. et al. V beta-specific stimulation of human T cells by staphylococcal toxins, Science, 244, 811, 1989.
114. Choi, Y. et al, Selective expansion of T cells expressing V beta 2 in toxic shock syndrome, J. Exp. Med., 172, 981, 1990.
115. Newton, D.W. et al, Mutations in the MHC class II binding domains of staphylococcal enterotoxin A differentially affect T cell receptor Vbeta specificity, J. Immunol., 157, 3988, 1996.
116. Leder, L. et al. A mutational analysis of the binding of staphylococcal enterotoxins B and C3 to the T cell receptor beta chain and major histocompatiblity complex class II, J. Exp. Med., 187, 823, 1998.
117. Gascoigne, N.R. and Ames, K.T, Direct binding of secreted T-cell receptor beta chain to superantigen associated with class II major histocompatiblity complex protein, Proc. Natl. Acad. Sci. USA, 88, 613, 1991.
118. Fields, B.A. et al, Crystal structure of a T-cell receptor beta-chain complexed with a superantigen, Nature, 384, 188, 1996.
119. Li, H. et al. Three-dimenstional structure of the complex between a T cell receptor beta chain and the superantigen staphylococcal enterotoxin B, Immunity, 9, 807, 1998.
120. Seth, A. et al, Binary and ternary complexes between T-cell receptor, class II MHC and superantigen in vitro, Nature, 369, 324, 1994.
121. Redpath, S. et al, Cutting edge: trimolecular interaction of TCR with MHC class II and bacterial superantigen shows a similar affinity to MHC:peptide ligands, J. Immunol., 163, 6, 1999.
122. Chatila, T. and Geha, R.S, Signal transduction by microbial superantigens via MHC class II molecules, Immunol. Rev., 131, 43, 1993.
123. Chatila, T. et al, Toxic shock syndrome toxin-1 induces inositol phospholipid turnover, protein kinase C translocation, and calcium mobilization in human T cells, J. Immunol., 140, 1250, 1988.
124. Scholl, P.R. et al, Role of protein tyrosine phosphorylation in monokine induction by the staphylococcal superantigen toxic shock syndrome toxin-1, J. Immunol., 148, 2237, 1992.
125. Trede, N.S. et al, Transcriptional activation of the human TNF-alpha promoter by superantigen in human monocytic cells: role of NF-kappa B, J. Immunol., 155, 902, 1995.
126. Sundstedt, A. et al, In vivo anergized CD4+ T cells express perturbed AP-1 and NFkappa B transcription factors, Proc. Natl. Acad. Sci. USA, 93, 979, 1996.
127. Krakauer, T, Induction of CC chemokines in human peripheral blood mononuclear cells by staphylococcal exotoxins and its prevention by pentoxifylline, J. Leuk. Biol., 66, 158, 1999.
128. Krakauer, T, Inhibition of toxic shock syndrome toxin-1 induced cytokine production and T cell activation by interleukin-10, interleukin-4, and dexamethasone, J. Infect. Dis., 172, 988, 1995.
129. Jupin, C. et al, Toxic shock syndrome toxin 1 as an inducer of human tumor necrosis factors and gamma interferon, J. Exp. Med., 167, 752, 1988.
130. Grossman, D. et al, Dissociation of the stimulatory activities of staphylococcal enterotoxins for T cells and monocytes, J. Exp. Med., 172, 1831, 1990.
131. Krakauer, T. and Stiles, B.G, Pentoxifylline inhibits superantigen-induced toxic shock and cytokine release, Clin. Diagn. Lab. Immunol., 6, 594, 1999.
132. Hale, M.L. et al, Pirfenidone blocks the in vitro and in vivo effects of staphylococcal enterotoxin B, Infect. Immun., 70, 2989, 2002.
133. Langezaal, I. et al, Evaluation and prevalidation of an immunotoxicity test based on human whole-blood cytokine release, Altern. Lab. Anim., 30, 581, 2002.
134. Hermann, C. et al. A model of human whole blood lymphokine release for in vitro and ex vivo use, J. Immunol. Meth., 275, 69, 2003.
135. Carlsson, R., Fischer, H., and Sjogren, H.O, Binding of staphylococcal enterotoxin A to accessory cells is a requirement for its ability to activate human T cells, J. Immunol., 140, 2484, 1988.
136. Trede, N.S., Geha, R.S., and Chatila, T, Transcriptional activation of IL-1 beta and tumor necrosis factor-alpha genes by MHC class II ligands, J. Immunol., 146, 2310, 1991.
137. Fischer, H. et al, Production of TNF-alpha and TNF-beta by staphylococcal enterotoxin A activated human T cells, J. Immunol., 144, 4663, 1990.
138. Lagoo, A. et al. IL-2, IL-4, and IFN-gamma gene expression versus secretion in superantigen-activated T cells, Distinct requirement for costimulatory signals through adhesion molecules, J. Immunol., 152, 1641, 1994.
139. Lando, P. et al, Regulation of superantigen-induced T cell activation in the absence and the presence of MHC class II, J. Immunol., 157, 2857, 1996.
140. Hewitt, C. et al, Major histocompatibility complex independent clonal T cell anergy by direct interaction of Staphylococcus aureus enterotoxin B with the T cell antigen receptor, J. Exp. Med., 175, 1493, 1992.
141. Stohl, W., Elliott, J.E., and Linsley, P.S. Human T cell-dependent B cell differentiation induced by staphylococcal superantigens, J. Immunol., 153, 117, 1994.
142. Mourad, W. et al, Engagement of major histocompatibility complex class II molecules by superantigen induces inflammatory cytokine gene expression in human rheumatoid fibroblast-like synoviocytes, J. Exp. Med., 175, 613, 1992.
143. Wooley, P.H. and Cingel, B, Staphylococcal enterotoxin B increases the severity of type II collagen induced arthritis in mice, Ann. Rheum. Dis., 54, 298, 1995.
144. Hodoval, L.F. et al, Pathogenesis of lethal shock after intravenous staphylococcal enterotoxin B in monkeys, Appl. Microbiol., 16, 187, 1968.
145. Raj, H.D. and Bergdoll, M.S, Effect of enterotoxin B on human volunteers, J. Bacteriol., 98, 833, 1969.
146. Adesiyun, A.A. and Tatini, S.R, Biological activity of cell-associated staphylococcal enterotoxin, J. Med. Primatol., 11, 163, 1982.
147. Scheuber, P.H. et al, Staphylococcal enterotoxin B as a nonimmunological mast cell stimulus in primates: the role of endogenous cysteinyl leukotrienes, Int. Arch. Allergy Appl. Immunol., 82, 289, 1987.
148. Scheuber, P.H. et al, Skin reactivity of unsensitized monkeys upon challenge with staphylococcal enterotoxin B: a new approach for investigating the site of toxin action, Infect. Immun., 50, 869, 1985.
149. Spiekermann, G.M. and Nagler-Anderson, C, Oral administration of the bacterial superantigen staphylococcal enterotoxin B induces activation and cytokine production by T cells in murine gut-associated lymphoid tissue, J. Immunol., 161, 5825, 1998.
150. Lu, J. et al, Colonic bacterial superantigens can evoke an inflammatory response and exaggerate disease in mice recovering from colitis, Gastroenterology, 125, 1785, 2003.
151. Sugiyama, H., Bergdoll, M.S., and Dack, G.M, Early development of a temporary resistance to the emetic action of staphylococcal enterotoxin, J. Infect. Dis., 111, 233, 1962.
152. McCormack, J.E. et al, Profound deletion of mature T cells in vivo by chronic exposure to exogenous superantigen, J. Immunol., 150, 3785, 1993.
153. Miethke, T. et al, Exogenous superantigens acutely trigger distinct levels of peripheral T cell tolerance/immunosuppression: dose-response relationship, Eur. J. Immunol., 24, 1893, 1994.
154. Collins, L.V. et al, Mucosal tolerance to a bacterial superantigen indicates a novel pathway to prevent toxic shock, Infect. Immun., 70, 2282, 2002.
155. Stiles, B.G. et al, Correlation of temperature and toxicity in murine studies of staphylococcal enterotoxins and toxic shock syndrome toxin 1, Infect. Immun., 67, 1521, 1999.
156. Bean, A.G. et al. Interleukin 10 protects mice against staphylococcal enterotoxin Binduced lethal shock, Infect. Immun., 61, 4937, 1993.
157. Hamad, A.R., Marrack, P., and Kappler, J.W, Transcytosis of staphylococcal superantigen toxins, J. Exp. Med., 185, 1447, 1997.
158. Buxser, S. and Bonventre, P.F, Staphylococcal enterotoxins fail to disrupt membrane integrity or synthetic functions of Henle 407 intestinal cells, Infect. Immun., 31, 929, 1981.
159. Lu, J. et al, Epithelial ion transport and barrier abnormalities evoked by superantigenactivated immune cells are inhibited by interleukin-10 but not interleukin-4, J. Pharm. Exper. Ther., 287, 128, 1998.
160. Harris, T.O. et al, Lack of complete correlation between emetic and T-cell-stimulatory activities of staphylococcal enterotoxins, Infect. Immun., 61, 3175, 1993.
161. Spero, L. and Morlock, B.A, Biological activities of the peptides of staphylococcal enterotoxin C formed by limited tryptic hydrolysis, J. Biol. Chem., 253, 8787, 1978.
162. Hovde, C.J. et al, Investigation of the role of the disulphide bond in the activity and structure of staphylococcal enterotoxin C1, Mol. Microbiol., 13, 897, 1994.
163. Stelma, G.N. and Bergdoll, M.S, Inactivation of staphylococcal enterotoxin A by chemical modification, Biochem. Biophys. Res. Commun., 105, 121, 1982.
164. Alber, G., Hammer, D.K., and Fleischer, B, Relationship between enterotoxic-and T lymphocyte-stimulating activity of staphylococcal enterotoxin B, J. Immunol., 144, 4501, 1990.
165. Reck, B. et al, Protection against the staphylococcal enterotoxin-induced intestinal disorder in the monkey by anti-idiotypic antibodies, Proc. Natl. Acad. Sci. USA, 85, 3170, 1988.
166. Hoffman, M. et al, Biochemical and mutational analysis of the histidine residues of staphylococcal enterotoxin A, Infect. Immun., 64, 885, 1996.
167. Hu, D-L. et al, Analysis of the epitopes on staphylococcal enterotoxin A responsible for emetic activity, J. Vet. Med. Sci., 63, 237, 2001.
168. Miethke, T. et al. T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor, J. Exp. Med., 175, 91, 1992.
169. Muller-Alouf, H. et al, Human pro-and anti-inflammatory cytokine patterns induced by Streptococcus pyogenes erythrogenic (pyrogenic) exotoxin A and C superantigens, Infect. Immun., 64, 1450, 1996.
170. Schlievert, P.M, Role of superantigens in human disease, J. Infect. Dis., 167, 997, 1993.
171. McCormick, J.K. et al, Functional characterization of streptococcal pyrogenic exotoxin J, a novel superantigen, Infect. Immun., 69, 1381, 2001.
172. Okusawa, S. et al. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition, J. Clin. Invest., 81, 1162, 1988.
173. Krakauer, T., Vilcek, J., and Oppenheim, J.J. Proinflammatory cytokines: TNF and IL-1 families, chemokines, TGF and others, in Fundamental Immunology, Paul, W., Ed., Raven Press, New York, 1998, chap. 21
174. Neumann, B. et al, Induction of acute inflammatory lung injury by staphylococcal enterotoxin B, J. Immunol., 158, 1862, 1997.
175. Sugiyama, H. et al, Enhancement of bacterial endotoxin lethality by staphylococcal enterotoxin, J. Infect. Dis., 114, 111, 1964.
176. Stiles, B.G. et al, Toxicity of staphylococcal enterotoxins potentiated by lipopolysaccharide: major histocompatibility complex class II molecule dependency and cytokine release, Infect. Immun., 61, 5333, 1993.
177. Chen, J.Y. et al, Increased susceptibility to staphylococcal enterotoxin B intoxication in mice primed with actinomycin D, Infect. Immun., 62, 4626, 1994.
178. Sarawar, S.R., Blackman, M.A., and Doherty, P.C, Superantigen shock in mice with an inapparent viral infection, J. Infect. Dis., 170, 1189, 1994.
179. Marrack, P. et al, The toxicity of staphylococcal enterotoxin B in mice is mediated by T cells, J. Exp. Med., 171, 455, 1990.
180. Dinges, M.M. and Schlievert, P.M, Comparative analysis of lipopolysaccharideinduced tumor necrosis factor alpha activity in serum and lethality in mice and rabbits pretreated with the staphylococcal superantigen toxic shock syndrome toxin 1, Infect. Immun., 69, 7169, 2001.
181. Dalpke, A.H. and Heeg, K, Synergistic and antagonistic interactions between LPS and superantigens, J. Endotoxin Res., 9, 51, 2003.
182. Dinges, M.M. and Schlievert, P.M, Role of T cells and gamma interferon during induction of hypersensitivity to lipopolysaccharide by toxic shock syndrome toxin 1 in mice, Infect. Immun., 69, 1256, 2001.
183. Stone, R.L. and Schlievert, P.M, Evidence for the involvement of endotoxin in toxic shock syndrome, J. Infect. Dis., 155, 682, 1987.
184. Paiva C.N. et al, Trypanosoma cruzi sensitizes mice to fulminant SEB-induced shock: overrelease of inflammatory cytokines and independence of Chagas’ disease or TCR V-usage, Shock, 19, 163, 2003.
185. Beno, D.W. et al, Differential induction of hepatic dysfunction after intraportal and intravenous challenge with endotoxin and staphylococcal enterotoxin B, Shock, 19, 352, 2003.
186. Beno, D.W. et al, Chronic staphylococcal enterotoxin B and lipopolysaccharide induce a bimodal pattern of hepatic dysfunction and injury, Crit. Care Med., 31, 1154, 2003.
187. Nagaki, M. et al, Hepatic injury and lethal shock in galactosamine-sensitized mice induced by the superantigen staphylococcal enterotoxin B, Gasteroent., 106, 450, 1994.
188. LeClaire, R.D. et al, Potentiation of inhaled staphylococcal enterotoxin B-induced toxicity by lipopolysaccharide in mice, Toxicol. Path., 24, 619, 1996.
189. Schlievert, P.M., Enhancement of host susceptibility to lethal endotoxin shock by staphylococcal pyrogenic exotoxin type C, Infect. Immun., 36, 123, 1982.
190. Sauter, C. and Wolfensberger, C, Interferon in human serum after injection of endotoxin, Lancet, 2, 852, 1980.
191. Chow, A. W. et al, Vaginal colonization with Staphylococcus aureus, positive for toxic-shock marker protein, and Escherichia coli in healthy women, J. Infect. Dis., 150, 80, 1984.
192. Yeung, R.S. et al. Human CD4 and human major histocompatibility complex class II (DQ6) transgenic mice: supersensitivity to superantigen-induced septic shock, Eur. J. Immun., 26, 1074, 1996.
193. Krakauer, T, Immune response to staphylococcal superantigens, Immunol. Res., 20, 163, 1999.
194. Hasko, G. et al, The crucial role of IL-10 in the suppression of the immunological response in mice exposed to staphylococcal enterotoxin B, Eur. J. Immunol., 28, 1417, 1998.
195. Blank, C. et al, Superantigen and endotoxin synergize in the induction of lethal shock, Eur. J. Immunol., 27, 825, 1997.
196. Saha, B. et al, Protection against lethal toxic shock by targeted disruption of the CD28 gene, J. Exp. Med., 183, 2675, 1996.
197. Mittrucker, H.W. et al, Induction of unresponsiveness and impaired T cell expansion by staphylococcal enterotoxin B in CD28-deficient mice, J. Exp. Med., 183, 2481, 1996.
198. Xu, H. et al, Leukocytosis and resistance to septic shock in intercellular adhesion molecule 1-deficient mice. J. Exp. Med., 180, 95, 1994.
199. Manjunath, N. et al, Negative regulation of T-cell adhesion and activation by CD43, Nature, 377, 535, 1995.
200. Mountz, J.D. et al, Increased susceptibility of fas mutant MRL-lpr/lpr mice to staphylococcal enterotoxin B-induced septic shock, J. Immunol., 155, 4829, 1995.
201. Sunstedt, A., Grundstrom, S., and Dohlsten, M. T cell-and perforin-dependent depletion of B cells in vivo by staphylococcal enterotoxin A, Immunol., 95, 76, 1998.
202. Miethke, T. et al, Bacterial superantigens induce rapid and T cell receptor V betaselective down-regulation of L-selectin (gp90Mel-14) in vivo, J. Immunol., 151, 6777, 1993.
203. DaSilva, L. et al. Human-like immune responses of human leukocyte antigen-DR3 transgenic mice to staphylococcal enterotoxins: a novel model for superantigen vaccines, J. Infect. Dis., 185, 1754, 2002.
204. Welcher, B.C. et al, Lethal shock induced by streptococcal pyrogenic exotoxin A in mice transgenic for human leukocyte antigen-DQ8 and human CD4 receptors: implications for development of vaccines and therapeutics, J. Infect. Dis., 186, 501, 2002.
205. Zhao, Y-X. et al, Overexpression of the T-cell receptor V beta 3 in transgenic mice increases mortality during infection by enterotoxin A-producing Staphylococcus aureus, Infect. Immun., 63, 4463, 1995.
206. Vlach, K.D., Boles, J.W., and Stiles, B.G, Telemetric evaluation of body temperature and physical activity as predictors of mortality in a murine model of staphylococcal enterotoxic shock, Comp. Med., 50, 160, 2000.
207. Boles, J.W. et al, Correlation of body temperature with protection against staphylococcal enterotoxin B exposure and use in determining vaccine dose-schedule, Vaccine, 21, 2791, 2003.
208. Hamel, M. et al, Activation and re-activation potential of T cells responding to staphylococcal enterotoxin B, Int. Immunol., 7, 1065, 1995.
209. Niedergang, F. et al. The Staphylococcus aureus enterotoxin B superantigen induces specific T cell receptor down-regulation by increasing its internalization, J. Biol. Chem., 270, 12839, 1995.
210. MacDonald, H.R. et al. Peripheral T-cell reactivity to bacterial superantigens in vivo: the response/anergy paradox, Immunol. Rev., 133, 105, 1993.
211. Sundstedt A. and Dohlsten, M, In vivo anergized CD4+ T cells have defective expression and function of the activating protein-1 transcription factor, J. Immunol., 161, 5930, 1998.
212. Florquin, S., Amraoui, Z., and Goldman, M. T cells made deficient in interleukin-2 production by exposure to staphylococcal enterotoxin B in vivo are primed for interferon-gamma and interleukin-10 secretion, Eur. J. Immunol., 25, 1148, 1995.
213. Hedlund, G. et al. Superantigen-based tumor therapy: in vivo activation of cytotoxic T cells, Cancer Immunol. Immunother., 36, 89, 1993.
214. Parsonnet, J. et al. A rabbit model of toxic shock syndrome that uses a constant, subcutaneous infusion of toxic shock syndrome toxin 1, Infect. Immun., 55, 1070, 1987.
215. Kim, Y.B. and Watson, D.W. A purified group A streptococcal pyrogenic exotoxin. Physiochemical and biological properties including the enhancement of susceptibility to endotoxin lethal shock, J. Exp. Med., 131, 611, 1970.
216. Huang, W.T., Lin, M.T., and Won, S.J, Staphylococcal enterotoxin A-induced fever is associated with increased circulating levels of cytokines in rabbits, Infect. Immun., 65, 2656, 1997.
217. Lee, P.K. and Schlievert, P.M, Quantification and toxicity of group A streptococcal pyrogenic exotoxins in an animal model of toxic shock syndrome-like illness, J. Clin. Microbiol., 27, 1890, 1989.
218. Huang, W.T., Wang, J.J., and Lin, M.T, Antipyretic effect of acetaminophen by inhibition of glutamate release after staphylococcal enterotoxin A fever in rabbits, Neurosci. Lett., 355, 33, 2004.
219. De Azavedo, J.C. and Arbuthnott, J.P, Toxicity of staphylococcal toxic shock syndrome toxin 1 in rabbits, Infect. Immun., 46, 314, 1984.
220. Pettit, G.W., Elwell, M.R., and Jahrling, P.B, Possible endotoxemia in rabbits after intravenous injection of Staphylococcus aureus enterotoxin B, J. Infect. Dis., 135, 646, 1977.
221. Fujikawa, H. et al, Clearance of endotoxin from blood of rabbits injected with staphylococcal toxic shock syndrome toxin-1, Infect. Immun., 52, 134, 1986.
222. Van Miert, A., Van Duin, C., and Schotman, A, Comparative observations of fever and associated clinical hematological and blood biochemical changes after intravenous administration of staphylococcal enterotoxins B and F (toxic shock syndrome toxin-1) in goats, Infect. Immun., 46, 354, 1984.
223. Wright, A., Andrews, P., and Titball, R.W, Induction of emetic, pyrexic, and behavioral effects of Staphylococcus aureus enterotoxin B in the ferret, Infect. Immun., 68, 2386, 2000.
224. Hu, D-L. et al, Induction of emetic response to staphylococcal enterotoxins in the house musk shrew (Suncus murinus), Infect. Immun., 71, 567, 2003.
225. Arad, G. et al, Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation, Nat. Med., 6, 414, 2000.
226. Shupp, J.W., Jett, M., and Pontzer, C.H, Identification of a transcytosis epitope on staphylococcal enterotoxins, Infect. Immun., 70, 2178, 2002.
227. LeClaire, R.D. et al, Protective effects of niacinamide in staphylococcal enterotoxin-B-induced toxicity, Toxicology, 107, 69, 1996.
228. Won, S-J. et al, Staphylococcal enterotoxin A acts through nitric oxide synthase mechanisms in human peripheral blood mononuclear cells to stimulate synthesis of pyrogenic cytokines, Infect. Immun., 68, 2003, 2000.
229. Saha, B. et al, Toxic shock syndrome toxin-1 induced death is prevented by CTLA4Ig, J. Immunol., 157, 3869, 1996.
230. Onai, H. and Kudo, S, Suppression of superantigen-induced lung injury and vasculitis by preadministration of human urinary trypsin inhibitor, Eur. J. Clin. Invest., 31, 272, 2001.
231. Takei, Y. et al, Tryptanthrin inhibits interferon-production by Peyer’s patch lymphocytes derived from mice that had been orally administered staphylococcal enterotoxin, Biol. Pharm. Bull., 26, 365, 2003.
232. Miller, E.J., Cohen, A.B., and Peterson, B.T, Peptide inhibitor of interleukin-8 (IL-8) reduces staphylococcal enterotoxin-A (SEA) induced neutrophil trafficking to the lung, Inflamm. Res., 45, 393, 1996.
233. Soltys, J. and Quinn, M.T, Modulation of endotoxin-and enterotoxin-induced cytokine release by in vivo treatment with beta-(1, 6)-branched beta-(1, 3)-glucan, Infect. Immun., 67, 244, 1999.
234. Eriksson, B.K. et al, Invasive group A streptococcal infections: T1M1 isolates expressing pyrogenic exotoxins A and B in combination with selective lack of toxin-neutralizing antibodies are associated with increased risk of streptococcal toxic shock syndrome, J. Infect. Dis., 180, 410, 1999.
235. Norrby-Teglund, A. et al, Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production, J. Immunol., 156, 3057, 1996.
236. Barry, W. et al, Intravenous immunoglobulin therapy for toxic shock syndrome, JAMA, 267, 3315, 1992.
237. Stegmayer, B. et al, Septic shock induced by group A streptococcal infection: clinical and therapeutic aspects, Scand. J. Infect. Dis., 24, 589, 1992.
238. LeClaire R.D., Hunt, R.E., and Bavari, S, Protection against bacterial superantigen staphylococcal enterotoxin B by passive vaccination, Infect. Immun., 70, 2278, 2002.
239. Woody, M.A. et al, Differential immune responses to staphylococcal enterotoxin B mutations in a hydrophobic loop dominating the interface with major histocompatibility complex class II receptors, J. Infect. Dis., 177, 1013, 1998.
240. Savransky, V. et al, Immunogenicity of the histidine-to-tyrosine staphylococcal enterotoxin B mutant protein in C3H/HeJ mice, Toxicon, 43, 433, 2004.
241. Bonventre, P.F. et al. A mutation at histidine residue 135 of toxic shock syndrome toxin yields an immunogenic protein with minimal toxicity, Infect. Immun., 63, 509, 1995.
242. Boles J.W. et al, Generation of protective immunity by inactivated recombinant staphylococcal enterotoxin B vaccine in nonhuman primates and identification of correlates of immunity, Clin. Immunol., 108, 51, 2003.
243. Bergdoll, M.S, Immunization of rhesus monkeys with enterotoxoid B, J. Infect. Dis., 116, 191, 1966.
244. Lowell, G.H. et al, Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines, Infect. Immun., 64, 4686, 1996.
245. Lowell, G.H. et al, Intranasal and intramuscular proteosome-staphylococcal enterotoxin B (SEB) toxoid vaccines: immunogenicity and efficacy against lethal SEB intoxication in mice, Infect. Immun., 64, 1706, 1996.
246. Tseng, J. et al, Humoral immunity to aerosolized staphylococcal enterotoxin B (SEB), a superantigen, in monkeys vaccinated with SEB toxoid-containing microspheres, Infect. Immun., 63, 2880, 1995.
247. di Tommaso, A. et al, Formaldehyde treatment of proteins can constrain presentation to T cells by limiting antigen processing, Infect. Immun., 62, 1830, 1994.
248. Cropley, I. et al, Mucosal and systemic immunogenicity of a recombinant, non-ADPribosylating pertussis toxin: effects of formaldehyde treatment, Vaccine, 13, 1643, 1995.
249. Rott, O. and Fleischer, B. A superantigen as virulence factor in an acute bacterial infection, J. Infect. Dis., 169, 1142, 1994.